BRAF and cancer: New specific therapies that will hopefully prolong survival are currently in development for patients with cancers harboring other oncogenic driver mutations such as BRAF, RET, NTRK etc. The introduction of immune checkpoint inhibitors has similarly changed former treatment paradigms.